Vera Therapeutics - Class A (VERA) closed at $30.03 on November 10, 2026, down 1.9% from the previous close, on volume of 1,545,664 shares (30-day average 1,633,870).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 28, 2026 | Calendar Call Spread | 20-Nov : 18-Dec-26 35 C | 2,000 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Bank of America Securities Remains a Buy on Vera Therapeutics (VERA)
TipRanks (Sat, 7-Nov 12:35 AM ET)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 4:05 PM ET)
Cantor Fitzgerald Reaffirms Their Buy Rating on Vera Therapeutics (VERA)
TipRanks (Fri, 6-Nov 9:47 AM ET)
Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Globe Newswire (Mon, 2-Nov 8:00 AM ET)
Globe Newswire (Thu, 22-Oct 10:05 AM ET)
Globe Newswire (Tue, 20-Oct 8:00 AM ET)
Globe Newswire (Fri, 2-Oct 9:24 AM ET)
Globe Newswire (Tue, 15-Sep 6:30 AM ET)
Vera Therapeutics to Participate at Upcoming Investor Conferences
Globe Newswire (Tue, 1-Sep 7:30 AM ET)
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Vera Therapeutics - Class A trades on the NASDAQ stock market under the symbol VERA.
As of November 11, 2026, VERA stock price climbed to $30.20 with 849,464 million shares trading.
VERA has a beta of 1.00, meaning it tends to be more sensitive to market movements. VERA has a correlation of 0.04 to the broad based SPY ETF.
VERA has a market cap of $2.17 billion. This is considered a Mid Cap stock.
Last quarter Vera Therapeutics - Class A reported $10 million in Revenue and -$1.30 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.34.
In the last 3 years, VERA traded as high as $56.05 and as low as $11.69.
The top ETF exchange traded funds that VERA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
VERA has underperformed the market in the last year with a return of +8.8%, while the SPY ETF gained +12.7%. In the last 3 month period, VERA fell short of the market, returning -4.4%, while SPY returned -1.4%. However, in the most recent 2 weeks VERA has outperformed the stock market by returning +0.7%, while SPY returned -1.2%.
VERA support price is $28.95 and resistance is $31.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERA shares will trade within this expected range on the day.
